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Introduction
From the second half of the twentieth century, advances in bio-
logical and psychopharmacological research seemed to promise a
swift discovery of an organic basis of psychiatric diseases. Today
we know that biological research in psychiatry is not a success story.
This may be due to the complicated character of psychiatric disor-
ders, where it is difficult to establish a unified model of the disease
and thus in many cases difficult to fit into any categorical classifica-
tion. This also affects the role of nuclear medicine (NM) in psychiatry.
Diagnosis in psychiatry
Today's diagnosis in psychiatry largely relies on the classifica-
tion of diseases following the criteria of the Diagnostic and Statis-
tical Manual of Mental Diseases (DSM-IV-TR-2000) [1]. This clas-
sification enabled better definition of nosological concepts and
better communication and understanding between psychiatrists.
On the other hand, DSM-IV does not entirely fit the psychiatric
diagnosis due to its rigid application of choice principle (five out
of nine symptoms).
There are two major problems in psychiatric diagnosis as a whole:
— diversity of symptoms — depressive episode patients may
be either agitated and insomniac, or with psychomotor retar-
dation and hypersomnia.
— overlapping symptoms — (sometimes defined as “co-morbid-
ity”); e.g. 30–60% of depressive patients may have co-morbid
anxiety disorder, whereas 40% diagnosed with anxiety have [2].
Diagnosis in psychiatry — the role
of neuroimaging
In the same way that the symptoms between different diseas-
es in psychiatry overlap, functional brain research frequently shows
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the same pattern of changes across diagnostic borders; on the
other hand, many the other tests, e.g. psychological tests, present
the same problem as mentioned above; therefore:
The psychiatrist seldom applies to an NM specialist to obtain
a diagnosis; instead, a nuclear medicine report will rather con-
firm, or less frequently exclude, the psychiatrist's diagnosis. Ideal-
ly, psychiatric patients should be rescanned after the treatment,
and changes in perfusion and/or metabolism discussed between
psychiatrist and NM specialist.
Applications of nuclear medicine
Applications of NM can be divided into:
I. Mostly diagnostic/practical/clinical:
— differential diagnosis of dementia;
— psychiatric sequelae of head trauma, including late whiplash
syndrome;
— neuropsychiatric lupus erythematosus.
II. With mixed/indeterminate status:
— psychiatric disorders in parkinsonian syndromes;
— chronic fatigue/myalgic encephalomyelitis.
III. Mostly investigational/experimental:
— other/most receptor studies.
Differential diagnosis of dementia
There are five potential major roles for neuroimaging with
respect to dementia:
— as a cognitive neuroscience research tool;
— for the prediction of which normal or slightly impaired indivi-
duals will develop dementia and over what time frame;
— for early diagnosis of Alzheimer's disease (AD) in demented
individuals, (sensitivity) and separation of AD from other forms
of dementia (specificity);
— for monitoring disease progression;
— for monitoring response to therapy.
Alzheimer's disease — SPECT studies
Single photon emission-computed tomography (SPECT) of
regional cerebral blood flow (rCBF) reaches detecting AD in up to
81%; although the clinical criteria may more sensitive (up to 81%),
SPECT seems superior in differentiating AD from the other types
of dementia (91% vs. 70%) [3]. Applying novel methodological
approaches such as means clustering or principal component
analysis has improved SPECT accuracies to as much as 98 and
90%, respectively [4].
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In SPECT studies, the typical finding is decreased blood
flow in the parietal or temporal lobe; in advanced cases with
poor prognosis, decreased blood flow in the frontal lobes is
also found. In mild cognitive impairment, rCBF SPECT studies
may differentiate patients who will convert to AD from non-con-
verters. Converters show reduced rCBF in bilateral temporo-
parietal areas and the precunei, compared with non-convert-
ers. The logistic regression model reveals that reduced rCBF in
the inferior parietal lobule, angular gyrus and precunei has
a high predictive value and discriminative ability [5]. The aceta-
zolamide test in rCBF SPECT is helpful to differentiate AD from
vascular dementia [6].
Following the therapy with acetyl cholinesterase inhibitors
(AChEI), the regional cerebral blood flow increases or remains
stable in AD patients with stabilized cognitive performance during
therapy, but decreases in non-responders [7].
Alzheimer’s disease — metabolic studies
[(18)F] fluorodeoxyglucose (FDG) possitron emission tomog-
raphy (PET) images of AD demonstrate a focally decreased cere-
bral metabolism especially involving the posterior cingulate and
neocortical association cortices, while largely sparing the basal
ganglia, thalamus, cerebellum and cortex mediating primary sen-
sory and motor functions.
In a multicentre study comprising 10 PET centres (Network for
Efficiency and Standardisation of Dementia Diagnosis, NEST-DD)
that employed an automated voxel-based analysis of FDG-PET
images, the distinction between controls and AD patients was 93%
sensitive and 93% specific, and even in very mild dementia (at
MMSE 24 or higher) sensitivity was still 84% at 93% specificity [8].
In very mild AD, both FDG-PET and voxel-based morphometry
(VBM-MRI) had high accuracies for diagnosis, but FDG-PET
showed a slightly higher accuracy than VBM-MRI. A combination
of the two techniques will yield a higher diagnostic accuracy in
very mild AD by making full use of functional and morphological
images [9].
In addition to glucose metabolism, specific tracers for dopam-
ine synthesis (18F-F-DOPA) and for (11C-MP4A) are of interest for
differentiation among dementia subtypes. Cortical acetylcholine
esterase activity (AChE) is significantly lower in patients with AD
or dementia with Lewy bodies (DLB) than in age-matched normal
controls. In LBD there is also an impairment of dopamine synthe-
sis, similar to Parkinson's disease.
Alzheimer’s disease
— imaging amyloid deposits
Pathologically, AD is characterised by the excess accumula-
tion of two types of protein aggregates: amyloid b-peptide (Ab)
plaques and neurofibrillary tangles.
Amyloid imaging with SPECT is possible with radioiodinated
styrylpyridines and hydroxybenzothiazoles [10], but today, practi-
cally, PET is the only available Ab imaging technique with the fol-
lowing agents:
— fluorophore derivative 18F-FDDNP [11];
— benzothiazole derivative 11C-PIB [12];
— stilbene derivative 11C SB-13 [13];
— 18F-fluoropegylated diphenylacetylenes [14].
Due to high costs, these modalities remain solely investiga-
tional.
Differential diagnosis of dementia — DLBD
Diffuse Lewy body dementia (DLBD) is the second most com-
mon type of degenerative dementia after AD and accounts for
15–20% of all autopsy-confirmed dementias in old age. Core clin-
ical features are progressive cognitive impairment, visual halluci-
nations and parkinsonian symptoms and signs. In DLBD there is
a pronounced cholinergic deficit, therefore, cholinergic medica-
tion gives better results, than in AD. In its early stages, DLBD brings
difficulties in differentiation with AD.
On rCBF SPECT scanning, patients show hypoperfusion in
parietal and occipital, and in frontal lobes, called “'horseshoe” signs
[15]. Combined studies of MMSE and brain SPECT achieved
a high discrimination between DLB and AD with a sensitivity of
81% and a specificity of 85%, suggesting that this is a useful and
practical approach to differentiate DLB from AD [16]. (18)F-FDG
PET showed significant glucose metabolic reductions in the tem-
poral, parietal and frontal areas (including the occipital lobe) com-
pared with those in the control group; in contrast, in AD patients,
both the hippocampal volume and glucose metabolism were sig-
nificantly decreased, whereas the occipital volume and metabo-
lism were preserved [17].
Fronto-temporal dementia
Fronto-temporal dementia (FTD) generally has a presenile on-
set, behavioural problems dominate the clinical picture and cogni-
tive functions are still relatively intact.
In rCBF SPECT studies, rCBF defect in frontal lobes in the left
temporoparietal-occipital discriminates FTD and AD and with
a sensitivity of 0.8 and specificity 0.65. [18, 19].
In PET studies in early stages of FTD, the neurodegenerative
process was found to be limited to the frontal lobes. During the
progression of the disease, the pathological changes pass over
the lobar borders and spread into the parietal and temporal corti-
ces [20]. In the late stages a significant hypometabolism is found
mostly in extensive prefrontal areas, cingulate gyri, anterior tem-
poral regions and the left inferior parietal lobule. Frontal hypome-
tabolism is usually more prominent in the left hemisphere than in
the right — in 79% of patients [21].
Therefore sociopathy in FTD may result from right fronto-
temporal dysfunction. In many jurisdictions, FTD patients with
sociopathy would not pass legal criteria for “not guilty” due to
insanity.
Dementia in Parkinson’s disease/
/Parkinsonian syndromes
Parkinson’s disease is a neurodegenerative disorder charac-
terised by progressive damage of the nigrostriatal dopaminergic
neurons in the basal ganglia. It accounts for up to 85% of patients
with parkinsonian symptoms.
Parkinsonian syndromes is a broader definition that encom-
passes other movement disorders with symptoms resembling PD
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and includes progressive supranuclear palsy (PSP), multiple sys-
tem atrophy (MSA) and corticobasal degeneration.
Confusingly, the symptoms of PD or PS can also be met in
patients with essential tremor or secondary to some medications.
Therefore, up to 25% of patients initially diagnosed as PD, later
have this diagnosis changed. 20–30% of patients with PD have
dementia; the crucial problem of diagnosing it with, for example,
MMSE are motor and speech disturbances.
PD patients with dementia show left temporo-parietal hypoper-
fusion as compared to a group of patients without dementia, which
resembles perfusion deficits described in Alzheimer’s disease.
Hypoperfusion of the left temporal lobe with an increase of rCBF
within the left thalamus might be clinically useful in the discrimina-
tion of Parkinson's disease patients with dementia from   those with-
out cognitive impairment [22].
Another aspect of RN diagnosis aims to differentiate PD and
essential tremor by 123I-b-CIT or 18F-DOPA uptake and differentiat-
ing PD and PS-plus syndromes with imaging of D2 receptors with
123I-IBZM [23–25].
Post-traumatic disorders
After head trauma a number of neuropsychiatric symptoms
and signs may follow, with considerable difficulties both in the
treatment and in medical certification of posttraumatic neuropsy-
chiatric disorders for the purpose of criminal and civil law pro-
ceedings.
Functional brain imaging data collected in a resting state can
provide objective evidence of brain injury in mild blunt head trau-
ma patients with persistent postconcussive somatic and/or cog-
nitive symptoms, particularly in mild and moderate traumatic brain
injury by better sensitivity than MR/CT findings and providing an
important exclusion role [26, 27], e.g. young patients following
head trauma 97% with negative rCBF SPECT findings develop
no post-traumatic disorder, whereas 95% with rCBF changes
do. RCBF SPECT scanning is particularly useful in imaging blood
flow disturbances in basal ganglia following head traumas, as
well as in mild brain injury [26–27]. The results of rCBF scanning
are important in rehabilitation counselling, medico-legal arguing
and the evaluation of the ability of the patient to work. Its limita-
tions overlap diffuse axonal injury (DAI), invisible in PET/SPECT,
and in older patients overlapping, for example, atherosclerotic
vascular lesions.
Late whiplash syndrome
The prevalence of whiplash injury is 4 cases per 1000 in-
habitants per year, usually following rear-end car collisions.
This sometimes results in whiplash-associated disorder (WAD),
a controversial condition with largely unknown pathogenetic
mechanisms. Only a small proportion (up to 5%) of whiplash
injury patients develop late whiplash syndrome with cerebral
symptoms: headache, dizziness, vertigo and concentration,
attention and memory disturbances, as well as peripheral
symptoms: neck pain, neck rigidity, temporomandibular dys-
function.
Being frequently secondary to traffic, sport and work related
accidents, late whiplash syndrome is a major medico-legal prob-
lem, of interest not only to physicians, but also to lawyers and
insurance companies.
Late whiplash syndrome
— triggering Alzheimer’s disease?
In 1997–2003 Otte et al. described an increased parieto/oc-
cipital hypoperfusion and hypothesized that LWS may trigger
Alzheimer's disease following prolonged hypoperfusion in the cor-
tico-basal region [28–30].
This hypothesis has been heavily criticized by many oppo-
nents, eg. Sundström and colleagues, who showed rCBF chang-
es in patients with chronic back pain of non-traumatic origin, but
not in those following whiplash injury [31], whereas some data
supports it [32].
Neuropsychiatric involvement in systemic lupus
erythematosus
The peak incidence of systemic lupus erythematosus (SLE)
occurs between 15 and 40 years of age. Central nervous system
(CNS) manifestations have been described in 20–70% of cases.
This dispersion alone illustrates the basic problem of cerebral in-
volvement in SLE, i.e. differentiating organic brain lesion from func-
tional disturbances, influence of medication — particularly ste-
roids, feelings of social rejection following skin changes, etc. Neu-
ropsychiatric manifestations in SLE comprise: migraine, epilepsy
and stroke, cognitive dysfunction, mood disorder, anxiety disor-
der, acute confusion state and psychoses.
Radionuclide studies help to distinguish organic brain lesions
and to differentiate from functional/iatrogenic changes. The clini-
cian expects a zero/one answer to the question: is there CNS in-
volvement or not?
As a “golden standard” of neuroimaging in neuropsychiatric
systemic lupus erythematosus (NP-SLE) is considered, MRI scan-
ning with white matter hyperintensities (WMH) as a marker of vas-
cular involvement. However, this appears in 30% of SLE patients
without CNS involvement and is absent in the early/intermediate
stages of the disease.
As a result, rCBF SPECT scanning is the most sensitive, al-
though not entirely specific for neuroradiological assessment in
NP SLE and other loose connective tissue diseases [33]. The high-
er sensitivity of SPECT, compared with MRI, can be explained by
the vasculopathy with microcirculation changes as a major patho-
logical factor in SLE.
18FDG PET scanning shows “posterior” type hypometabolism
as a typical finding [34].
Schizophrenia
Schizophrenia is a major source of morbidity worldwide, with
a prevalence of about 1% and significant disablement. RN neu-
roimaging is focused on receptor research, with few results, mostly
indicating disturbances of dopamine in schizophrenia, but this is
unlikely to be the whole story. As new ligands are developed, fur-
ther insights will be gained into the underlying pathology of schizo-
phrenia; new techniques combining functional imaging with ge-
netic studies are likely to not only depict the state of receptor pop-
ulations, but also concentrate on long-term dynamic changes in-
duced by the illness and its treatment.
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Schizophrenia — the dopamine overactivity
hypothesis
This hypothesis says that increased activity in the dopamine
neurotransmitter system is responsible for the positive symptoms
of schizophrenia. An increased density of D2 receptors was found
in post-mortem studies [35].
Early studies revealed a marked increased in D2 binding with-
in the striatum. Further studies revealed two distinct families of
dopamine receptors: D1
– like (D1 and D5) and D2
– like (D2, D2, D4).
It could be that the antipsychotic drug selectivity could be due to
preferential binding of dopamine D2–like receptors.
For measuring dopamine synthesis and transport in presyn-
aptic function for the former, the most commonly used tracers are
6-[(18)F]FDOPA and 6-[(18)F]FMT, whereas for the latter, several
(11)C/(18)F-labelled tropane analogues are being clinically used.
Postsynaptically, dopamine exerts actions through several sub-
types of the dopamine receptor [36].
In schizophrenia, dopamine studies of receptor competition
of 123I-IBZM, a dopamine D2 ligand with dopamine, showed that
not only resting dopamine levels matter, but also suggested that
schizophrenia is a disorder of dopamine dysregulation in different
parts of the brain. In treatment follow-up, increasing D2 receptor
occupancy on the 2nd SPECT was a predictive factor for the re-
lapse; therefore, D2 receptor occupancy and its changes during
quetiapine therapy is thought to be related to the prognosis of the
treatment efficacy [37].
Schizophrenia — 5HT receptors
An interest in the role of 5HT2a receptors in schizophrenia was
aroused by the observation that serotoninergic agents, such as
LSD, led to hallucinations. Initial SPECT and PET studies showed
a very high occupancy of 5HT2a receptors for many atypical antip-
sychotic drugs including clozapine, olanzapine and risperidone
but not typical ones like haloperidol and chlorpromazine. The in-
volvement of 5HT2a receptors was undermined by the fact that its
pure antagonists did not have any antipsychotic effect. More re-
cent papers on 5HT1a have shown increased binding in schizo-
phrenics in the left mediotemporal cortex, but the meaning of this
is unclear [38]. The current view is that changes in this receptor
population are unlikely to be a causal factor in schizophrenia.
Schizophrenia — glutamate and NMDA receptors
N-Methyl-D-aspartate (NMDA) receptors are calcium-perme-
able glutamate receptors that play putative roles in learning, mem-
ory and excitotoxicity. There has been much interest over the years
in the NMDA receptors in schizophrenia, as certain blockers of
NMDAR such as PCP and ketamine lead to transient drug-induced
symptoms very similar to those reported by schizophrenic pa-
tients. The first in vivo evidence of an NMDA receptor deficit in
medication-free schizophrenic patients was published in 2006 [39].
Mood disorders
Mood disorders are amongst the most prevalent in modern
society and have an important socio-economic impact.
Diagnosing depression is based upon fulfilling five criteria
of the American Psychiatric Association/DSM-IV, including at
least “depressed mood” or “diminished interest of pleasure”
during the same 2-week period. The presence of manic or hy-
pomanic episodes further specifies whether the disorder is un-
ipolar or bipolar.
The course specifiers describe the severity of the last episode,
from mild to severe, and the course of disorders, e.g. recurrent,
with seasonal pattern or with rapid cycling pattern; other specifi-
ers describe atypicality, postpartum onset and the presence of
catatonic features or chronicity.
Brain perfusion and metabolism studies
in depressive disorders
Early studies by Baxter et al. described a globally decreased
supratentorial brain activity in bipolar disorders. With metabolic
rate increasing while going from depression to euthymic or manic
state, further studies showed a significant left-right prefrontal asym-
metry, resolving after treatment. Hypoperfusion in recurrent de-
pressive disorders was considerably greater (nearly significant) in
comparison with the first depressive episodes [40]
Further studies refined the findings of prefrontal hypoperfu-
sion/metabolic hypoactivity, as the most important delineating
those findings to areas of the prefrontal cortex and its functional-
ly separate areas: dorsolateral (DLPFC), the orbito-frontal and
anterior cingulate, left amygdala, parahippocampal gyrus [41,
42], which with subcortical circuits have separate behavioural
functions: DLPFC mediating executive functions, orbito-frontal
object-affect associations and anterior cingulate mediating mo-
tivation.
Mood disorders — treatment effects
Nearly all available antidepressants have been studied. Nor-
malisation of the frontal hypoperfusion/ hypometabolism and/or
asymmetry appears to be the most replicative finding [43, 44].
In many studies a pattern of cortical flow/metabolism increas-
es and limbic/paralimbic decreases was seen in association with
chronic treatment, which suggest primary subcortical and limbic
effects of pharmacological treatment, with neocortical effects as
secondary [45].
Electroconvulsive therapy (ECT), a powerful tool where phar-
macological intervention fails, initially reduces the CBF and me-
tabolism in the short term, suggesting the reduction of neural ac-
tivity; in the long-term, normalising perfusion/metabolism in de-
pressed patients [43, 46]. However, ECT flow/metabolism results
may be atypical, as this therapy is mostly applied in treatment-
resistant patients.
Repetitive transcranial magnetic stimulation (rTMS) of the pre-
frontal cortex may be useful in refractory cases. High-frequency
rTMS of the left prefrontal cortex and possibly of the opposite
physiological effects low frequency rTMS of the right prefrontal
cortex produce a significant decrease in Hamilton depressing scale
scores; it increases the metabolic rate in the prefrontal cortex,
amygdala, basal ganglia, hippocampus and cerebellum; post-
treatment a decrease in cingulate [47].
Vagal nerve intermittent electrical stimulation, used mostly in
epilepsy treatment, also reduces depressive symptoms. rCBF
changes share features with changes of rCBF previously associ-
ated with the administration of selective serotonin reuptake inhib-
itors. Similarities to other brain-stimulation strategies in antidepres-
sant treatment were less pronounced [48].
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Radioligand receptor studies in depression
These studies are limited mainly by the availability of suitable
ligands. Currently available ligands allow the investigation of
5-HT1A [11C-WAY-100635], 5-HT2A [
123I -ketanserin, 18F-altanserin,
and 11C-methylpiperone] and D2 receptors [
123I-IBZM]. The results
are rather discordant [49, 50].
Most, albeit not all, studies find an increased 5-HT2A binding
after treatment, the same effect in D2 binding and a decrease in
HT1A binding.
The current status of ligand studies in depression does not
yet allow for the tailoring of the pharmacotherapeutic status in
individual patients. They allow at least some agreement as to the
effect of antidepressant agents on the HT and dopamine recep-
tors and on serotonin transporters.
There are two conclusions about radionuclide studies in de-
pression: good news: brain imaging is a powerful tool to explore
various aspects of brain function in depression; bad news: the
clinical psychiatrist should not ask the nuclear medicine psychia-
trist to confirm the diagnosis of depression in his patients — hy-
pofrontality is quite an unspecific finding. Performing functional
imaging, however, should stimulate both specialists to look at func-
tional abnormalities on the scan and to link them to the patients’
behavioural abnormalities and/or symptoms.
Future research should be devoted to finding the basics of
treatment regimens and finding predictors of treatment re-
sponse.
Obsessive-compulsive disorder
Obsessive-compulsive disorder (OCD) is characterised by
repetitive thoughts, impulses, images or behaviours. The obses-
sions or compulsions interfere significantly with the person's nor-
mal life as well as occupational and social functioning.
Neuroimaging studies have proved that the evidence of the
dysfunction of the fronto-subcortical circuit might be involved in
the pathophysiology of OCD. In SPECT and PET studies hyperac-
tivities of those circuits, including orbito-frontal cortex, anterior cin-
gulate and/or basal ganglia, have been a consistent finding [51].
Serotonin transporter studies indicate a reduced serotonergic
input into the fronto-subcortical circuits in OCD, thereby diminish-
ing the inhibitory regulation of serotonin in these circuits [52].
Fluvoxamine treatment significantly improves clinical symptoms
and increases D2 ligand [(11)C]-raclopride binding potential (BP)
in the basal ganglia of OCD patients. (Chronic treatment with flu-
voxamine induces a slight but significant increase in striatal [(11)C]-
-raclopride binding of previously drug-naive OCD patients [53].
Although present imaging techniques have limitations as
a means of brain dysfunction in OCD, nuclear neuroimaging may
be used as an objective tool and as a way to predict a response
to the treatment.
Eating disorders
Eating is part of basic human behaviour. Therefore, eating
disorders are relative rare within the domain of psychiatry. There
are two major pathological entities: anorexia nervosa and bulimia
nervosa. On the other hand, a separate major issue is the investi-
gation of the CNS in binge-eating and obesity: a major epidemic
problem. Many obese patients probably suffer from binge-eating
disorders, but this is certainly not always objectified and is even
overlooked.
Functional brain imaging in eating disorders has been avail-
able for more than a decade. Generally there is an enormous dif-
ferentiation between studies, and they may be secondary to meth-
odological variations. Therefore they are of limited, or even no
clinical value, at least at present, although they may give some
guidance to future pharmacological studies.
Anorexia nervosa
Anorexia nervosa (AN) is a devastating and life-threatening
disease. Among females, its prevalence is approximately 0.27–
1% [54]. There are two subtypes: in the RAN subtype, dieting,
fasting or excessive exercise is used to achieved weight loss; the
binge-eating/purging type involves a combination of binge eating
and purging by means of self-induced vomiting and/or misuse of
laxatives, diuretics and enemas.
Patients with anorexia nervosa show either hyperperfusion in
the frontal, fronto-temporal and parietal cortex or hypoperfusion
in the anterior cingulate. Activation tests show an rCBF increase
in the left inferior frontal lobes. Following treatment, changes of
rCBF in the right DLPFC, ACC, MPFC, PCC and precuneus are
related to the AN recovery process and might be associated with
the improvement of interoceptive awareness [55].
Receptor [18F-altanserin] HT2A studies showed reduced tracer
binding with altered neurotransmission during recovery. The ques-
tion remains, whether it is a cause or consequence of AN.
There are two basic technical problems in the assessment of
AN patients: rCBF changes are either small and space-restricted
or diffuse and unspecific. This requires either good quality statis-
tical parametric mapping (SPM) or activation paradigms utilising
food stimuli in a well-standardized environment.
Bulimia nervosa
Bulimia (Greek — bull hunger) is generally considered a con-
dition in which the subject engages in recurrent binge eating fol-
lowed by an intentional purging. This purging is done in order to
compensate for the excessive intake of food and to prevent weight
gain. Purging typically takes the form of vomiting; inappropriate
use of laxatives, enemas and other medication and/or excessive
physical exercise. Historically, it was initially considered a variant
of anorexia nervosa.
SPECT studies showed decreased right inferior frontal and
left temporal lobes. This may suggest hypoactivity of the putative
feeding suppression mechanism in the frontal lobe, resulting in
hyperphagia. Alterations in rCBF during the ill state of BN may be
a state-related phenomenon that remits with recovery [56].
PET study data showed — contrary to depressive patients
— maintained basal ganglia metabolism. Some PET studies
showed lower rCMRGlu patterns similar to those of obsessive-
-compulsive disorder symptoms.
Receptor studies suggest decreased serotonergic transmis-
sion in bulimia nervosa. Studies using PET with serotonin specific
radioligands implicate alterations of 5-HT1A and 5-HT2A recep-
tors and the 5-HT transporter. Alterations of these circuits may
affect mood and impulse control as well as the motivating and
hedonic aspects of feeding behaviour [57].
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Obesity
Obesity is an epidemic of our age, at least in some countries;
therefore, functional brain studies in obesity seem very promis-
ing. rCBF SPECT studies in obese women showed higher CBF in
the right parietal and temporal cortices during food exposure than
in control conditions. In addition, in obese women the activation
of the right parietal cortex was associated with an enhanced feel-
ing of hunger when looking at food. No such changes or associ-
ations were seen in normal-weight women [58].
In PET studies, higher metabolic activity was shown in the area
of the parietal cortex where the somatosensory maps of the mouth,
lips and tongue are located, suggesting the role of a reward com-
ponent in the aetiology of obesity. Another study showed the in-
volvement of enhanced sensitivity of the frontal regions following
food stimuli, suggesting their specific response.
Receptor studies with 11C-raclopride showed the negative
correlation of BMI and D2 receptor availability [59].
Social anxiety disorder
Social anxiety disorder (SAD) is characterised by the fear of
social interaction and performance situations. A person fears that
he or she will act in a way that will be humiliating or embarrassing
[DSM-IV]. In the course of the disease, secondary depression or
subsequent alcohol abuse and dependence may develop.
rCBF SPECT scanning data are similar to those of other
anxiety disorders and are consistent with previous work demon-
strating the importance of limbic circuits in this spectrum of disor-
ders. These play a crucial role in cognitive-affective processing,
are innervated by serotonergic neurons, and changes in their ac-
tivity during serotonergic pharmacotherapy seem crucial [60].
Serotonin receptor studies showed that the lower 5-HT1A bin-
ding in the amygdala and mesiofrontal areas of SAD patients was
consistent with a previous PET study in healthy volunteers sho-
wing an inverse correlation between 5-HT1A BP and state anxiety
and other human PET studies in patients with panic disorders
showing reduced 5-HT1A binding, thus corroborating the potential
validity of 5-HT1A receptors as targets in the treatment of human
anxiety disorders [61].
Dopamine receptor studies showed that striatal dopamine re-
uptake site densities were markedly lower in patients with social pho-
bias than in the age- and gender-matched comparison subjects.
These results indicate that social phobia may be associated with
a dysfunction of the striatal dopaminergic system [62].
Functional brain imaging in court
PET and SPECT studies are increasingly used as tools in
forensic medicine, particularly in the USA since the start of the
nineties. The mental disorders which attract the most legal at-
tention are those where a connection is made to an injurious
stimuli, e.g. post-traumatic brain injury or post-traumatic stress
disorder. The brain changes are not clear in all patients; there-
fore, functional neuroimaging cannot be safely used to make
diagnosis of psychiatric disorders or to exclude/confirm psychi-
atric disorders, so its use is limited to that of an auxiliary tool
together with CT, MRI and psychometric testing, although some
specific reports exist [63, 64].
In order to be accepted as evidence, the Supreme Court of
the USA ruled that the following elements should be taken into
account assessing the diagnostic method [65]:
— can the particular method be tested?
— are the known/potential pitfalls of the method established?
— is there sufficient scientific evidence about the method?
— is there wide acceptance of the method in the scientific world?
In most cases, PET and SPECT fulfil the above-mentioned
demands, at least partly, due to the scarce number of controlled
studies, low sensitivity and specificity, and insufficient standardis-
ation. The have, therefore, used in only a few situations: traumatic
brain injury following car accidents or criminal attacks, in confir-
ming/excluding brain injury in victims with unspecific complaints
such as persistent headaches, amnesia emotional disorders etc.,
organic basic brain dysfunction e.g. frontal syndrome in suspects,
or post-traumatic stress disorder (PTSD) in war veterans.
Post-traumatic stress disorder
Post-traumatic stress disorder (PTSD) is a complex psycho-
biological disorder which develops in the aftermath of severe and/
/or life-threatening trauma (coma, burns, sexual abuse). Functional
imaging in PTSD is in its infancy, but the body of evidence is grow-
ing, and through these insights PTSD has changed from “trauma-
tic neurosis” to a biologically based psychological disorder. This
anxiety disorder is most likely associated with changes in neural
circuitry involving the frontal and limbic systems. The altered me-
tabolism in these brain structures after a traumatic event is corre-
lated to PTSD. Developments in the field of neuroimaging have
allowed researchers to look at the structural and functional pro-
perties of the brain in PTSD [66].
Neuroimaging studies are usually performed as emotional
activation studies, utilising e.g. combat-related sounds, images
of a great fire, etc. [67, 68]; therefore, such studies are some-
times difficult to perform for ethical reasons.
Emotional activation studies demonstrate flow/metabolic ac-
tivation most frequently in the precentral gyrus, posterior cingu-
late, amygdala and cerebellum, while deactivation is seen in the
middle temporal gyrus, and inferior and middle frontal and pari-
etal region.
Preliminary data show the circuits in the brain connecting re-
gions of the medial prefrontal, medial temporal, frontal and pari-
etal cortices. The future of such studies will probably help in un-
derstanding what makes some people more vulnerable to PTSD
and how treatment influences and predicts the changes we see in
brain imaging studies.
Brain function during hypnosis
Hypnosis may be defined as a state of focused attention, con-
centration and inner absorption with a relative suspension of pe-
ripheral awareness.
PET studies demonstrated a vast activation in the occipital
parietal, precentral prefrontal and cingulate cortex. This suggests
that the hypnotic state does not rely on simple evocation of epi-
sodic memory but a reminiscence of mental imagery [69].
PET studies have given neuroimaging support for the nocice-
ptive effect of hypnosis;  the hypnotic state significantly enhances
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the functional modulation between the midcingulate cortex and
the large neural network involved in sensory, affective, cognitive
and behavioural aspects of nociception [70]. In fibromyalgic pa-
tients under hypnosis, the cerebral blood-flow was bilaterally in-
creased in the orbitofrontal and subcallosal cingulate cortices, the
right thalamus and the left inferior parietal cortex, and was de-
creased bilaterally in the cingulate cortex. The observed blood-
flow pattern supports notions of a multifactorial nature of hypnotic
analgesia, with interplay between cortical and subcortical brain
dynamics [71].
Impulsive aggression and suicidal behaviour
Impulsive aggressive behaviour including deliberate self-harm
and impulsive aggression towards others as well as suicidal be-
haviour is a major problem in healthcare. It is believed that its
anatomical correlates are the prefrontal and temporal limbic re-
gions and serotoninergic dysfunction plays a crucial role.
In impulsitivity, PET studies indicate that the impulsivity
and chronic stress are associated with amphetamine-induced
stria-tal dopamine release. In PET studies with high specific
activity, [11C] raclopride was associated with blunted right
ventral striatal DA release. Dopamine release was greater in
low vs. high impulsivity subjects under conditions of low or
moderate stress [72].
In suicidal behaviour, direct in vivo functional imaging with
PET or SPECT demonstrated a reduction in the 5-HT2A binding
index in suicide attempts by anxious and depressed suicide at-
tempters and an increase in 5-HT2A binding in impulsive suicide
attempters [73]. The importance of such studies is two-fold: first
this may increase insight into the pathophysiology of impulsive
aggression; secondly this may enable the development of new
pharmacological approaches.
Hysteria and catatonia
Hysteria (conversion disorder)
The neural concomitants of hysteria and catatonia remain
largely unknown. Hysteria, or conversion disorder, is defined as
a psychiatric illness the symptoms or deficits of which, affecting
voluntary motor or sensory function, cannot be explained by
a neurological or general medical condition.
Functional neuroimaging has revealed selective decreases in
the activity of frontal and subcortical circuits involved in motor
control during hysterical paralysis, decreases in somatosensory
cortices during hysterical anaesthesia, or decreases in the visual
cortex during hysterical blindness [74]. The inhibition of normal
neural networks seem to also be a common marker to tunnel vi-
sion or hysterical deafness.
Catatonia
In catatonic patients, SPECT and PET studies showed dys-
functions of prefrontal and parietal cortices that possibly ac-
count for its motor, affective and behavioural disorders. Dys-
functions in the prefrontal cortex could account for some affec-
tive disturbances found in catatonia, whereas dysfunction in
parietal lobes might participate in the disturbances of execu-
tive task planning.
In akinetic catatonia, SPECT and PET studies showed dys-
functions of the medial, prefrontal cortex, lateral parietal cortex
and precuneus, which are known to be involved in conscious
awareness [75].
The studies mentioned support the argument for the exist-
ence of a neural network of conscious awareness that may be
disturbed in patients with stuporous catatonia.
Sleep disorders
One-third of our lives are occupied by sleep. The utilization of
nuclear medicine in sleep disorders is still in its infancy; this may
be, however, a promising area for future development.
In healthy sleep there is an increase in function in the limbic
and anterior paralimbic cortex in REM sleep and a decrease in the
function of the higher cortical regions in known thalamocortical
networks during NMREM sleep. Serotonin 5HT1A receptor PET
studies showed a significant increase in their ligand-[18F]MPPF
binding in sleep compared to wakefulness in the whole brain and
all regions of interest examined: temporal cortex, mesial temporal
region and cingulate cortex [76].
There is a collection of papers on diverse sleep disorders such
as: sleep deprivation, insomnia, dyssomnia, narcolepsy, sleep
apnoea and sleepwalking.
Perfusion abnormalities in patients with REM behaviour disor-
der are located in the brainstem, striatum and cortex. These ab-
normalities are consistent with the anatomic metabolic profile of
Parkinson's disease [77].
In primary insomnia a pattern of hypoperfusion in the frontal
medial, occipital and parietal cortices was found with particular
deactivation in the basal ganglia [78].
In narcolepsy SPM analysis of the brain, SPECT showed hy-
poperfusion of the bilateral anterior hypothalami, caudate nuclei,
and pulvinar nuclei of the thalami, parts of the dorsolateral/ventro-
medial prefrontal cortices, parahippocampal gyri and cingulate
gyri in narcoleptics, as well as reduced cerebral perfusion in sub-
cortical structures and cortical areas in narcoleptics. The distribu-
tion of abnormal cerebral perfusion is concordant with the path-
way of the cerebral hypocretin system and may explain the cha-
racteristic features of narcolepsy, i.e. cataplexy, emotional lability
and attention deficit [79].
In sleepwalking, activation of thalamocingulate pathways and
persisting deactivation of other thalamocortical arousal systems
was found [80].
Conclusions
As shown above, there are few practical applications of nu-
clear medicine due to low specificity and low spatial resolution,
although in the aspect of functional imaging it is still superior to
CT/MRI, even in their functional modalities.
On the other hand, its investigational potential is still growing,
as there is no imaging technique in sight which could replace
metabolic and receptor studies, and also because the scope of
functional imaging in psychiatric diseases is spreading from its
traditional applications, like dementia or depression, towards many
poorly investigated fields e.g. hypnosis, suicidal behaviour or sleep
disorders.
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